Monobody could be key in fighting 30% of cancers

Chicago skyline
Chicago skyline--Courtesy of Daniel Schwen/CC BY-SA 4.0

While scientists have long studied mutations of the RAS oncogene as a target for new cancer drugs, they have been unable to pinpoint a drug that safely blocks its effects. Now, a team from the University of Illinois at Chicago (UIC) has identified a monobody that can block the oncogene’s activity.

RAS mutations appear in almost 30% of all cancers, according to a statement. They are also present in nearly 90% of pancreatic cancers and occur frequently in colon cancer, lung cancer and melanoma. There are three RAS proteins: K-RAS, H-RAS and N-RAS.

The UIC researchers took a different tack: “We did not look for a drug or specifically for an inhibitor,” said John O’Bryan, an associate professor of pharmacology at the UIC College of Medicine, in the statement. “We used monobody technology, a type of protein-engineering technology, to identify regions of RAS that are critical for its function.”

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

The team found that a synthetic binding protein, dubbed the NS1 monobody, was able to inhibit RAS protein activity. Monobodies have been used to target a variety of proteins, such as enzymes and cell receptors, according to the statement. Unlike regular antibodies, O’Bryan said, monobodies are not dependent on their environment and can be used as genetically encoded inhibitors. When a monobody binds to a protein--in this case, RAS proteins--it generally acts as an inhibitor of that protein, he said.

The NS1 monobody works by binding to a spot on the RAS protein molecule, thereby inhibiting its oncogenic activity, according to the statement. It blocks the oncogenic function of two out of the three RAS proteins by preventing the protein from joining an identical molecule to form a pair.

While further studies and trials are required before moving the monobody out of the lab, the findings could lead to new therapies for various cancers that work by targeting mutant RAS activity in cancer cells. This could be especially important for melanoma, the deadliest of the skin cancers, and for pancreatic cancer, of which a diagnosis can often mean a death sentence.

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.